Immunology-Focused Coultreon Adds $125M for Pills That Pack the Punch of Injectable Biologics
Coultreon Biopharma’s lead drug candidate, acquired from Galapagos, is a small molecule designed to selectively…
Immunology-Focused Coultreon Adds $125M for Pills That Pack the Punch of Injectable Biologics
Coultreon Biopharma’s lead drug candidate, acquired from Galapagos, is a small molecule designed to selectively inhibit a novel immunology target called SIK3. The Series A financing will support Phase 2 clinical trials in psoriasis and ulcerative colitis. The post Immunology-Focused Coultreon Adds $125M for Pills That Pack the Punch of Injectable Biologics appeared first on…
Executing Biologics Technology Transfer through Integrated Operating Models
As biologics modalities diversify and processes grow complex, the success of tech transfer depends on integrated execution rather than each procedural completion. The post Executing Biologics Technology Transfer through Integrated Operating Models appeared first on MedCity News.
Digitizing Medical Policy Alone Will Not Automate Prior Authorization at Scale
Many health plans are discovering that even after digitizing medical policies and implementing FHIR APIs, prior authorization turnaround times remain slow and provider frustration remains high. The reason is straightforward: digitization alone does not make medical‑necessity determinations executable by automated systems at scale. The post Digitizing Medical Policy Alone Will Not Automate Prior Authorization at…
As Health Costs Hit Record Highs, Brokers Face a Structural Test
This is forcing brokers to rethink how they serve clients and how their businesses continue to grow without sacrificing service. The post As Health Costs Hit Record Highs, Brokers Face a Structural Test appeared first on MedCity News.
Health Care’s AI Disruption, Ready or Not
The AI revolution is already here — but what does it mean for patients, clinicians, and health care industry leaders? Eric Larsen, veteran health care strategist and longtime advisor to CEOs across the industry, joins host Chip Kahn for a discussion about why the U.S. health care industry is uniquely exposed to AI-driven disruption and…
It’s Got a Good Beat and You Can Kill It
By KIM BELLARD Most of us can identify dogs from cats just by the sounds they make. We could probably even separate a dog’s bark from a wolf’s howl. If you are a nature lover, you might be able to identify different species of birds by their calls. If you are a cetologist, you might…
CMMI’s Advancing Chronic Care with Effective Scalable Solutions (ACCESS) Model Explained
In May 2025, CMS’s Center for Medicare & Medicaid Innovation (CMMI) unveiled it’s “Make America Healthy Again” vision. CMMI models focus on not only “protecting the federal taxpayer,” but also (i) promoting evidence-based prevention, (ii) empowering people to achieve their health goals, and (iii) driving choice and competition for people. CMMI has introduced a number…
Why Healthcare AI Still Can’t Scale — and How Nvidia & Hoppr Are Trying to Fix It
Nvidia and Hoppr are betting that healthcare AI will scale not through standalone applications, but through a new infrastructure layer that lets providers develop and deploy their own imaging models. The post Why Healthcare AI Still Can’t Scale — and How Nvidia & Hoppr Are Trying to Fix It appeared first on MedCity News.
CEO of For-Profit MA Plan Tells CMS “Pay Us Less”
Ed Park is sincere and passionate about his calling as the CEO of Devoted Health, which provides Medicare Advantage plans to seniors in 29 states. But it remains to be seen if he can do more or the same with less. The post CEO of For-Profit MA Plan Tells CMS “Pay Us Less” appeared first…
Timely by DrFirst Aims to Lower Barriers to Specialty Meds
Timely by DrFirst launched a tool to streamline prior authorizations and improve access to specialty medications. The post Timely by DrFirst Aims to Lower Barriers to Specialty Meds appeared first on MedCity News.
